245 related articles for article (PubMed ID: 31954715)
21. miRConnect 2.0: identification of oncogenic, antagonistic miRNA families in three human cancers.
Hua Y; Larsen N; Kalyana-Sundaram S; Kjems J; Chinnaiyan AM; Peter ME
BMC Genomics; 2013 Mar; 14():179. PubMed ID: 23497354
[TBL] [Abstract][Full Text] [Related]
22. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections.
Marchini S; Cavalieri D; Fruscio R; Calura E; Garavaglia D; Fuso Nerini I; Mangioni C; Cattoretti G; Clivio L; Beltrame L; Katsaros D; Scarampi L; Menato G; Perego P; Chiorino G; Buda A; Romualdi C; D'Incalci M
Lancet Oncol; 2011 Mar; 12(3):273-85. PubMed ID: 21345725
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-200c and microRNA-141 as potential diagnostic and prognostic biomarkers for ovarian cancer.
Gao YC; Wu J
Tumour Biol; 2015 Jun; 36(6):4843-50. PubMed ID: 25636451
[TBL] [Abstract][Full Text] [Related]
24. Circulating epithelial-mesenchymal transition-associated miRNAs are promising biomarkers in ovarian cancer.
Márton É; Lukács J; Penyige A; Janka E; Hegedüs L; Soltész B; Méhes G; Póka R; Nagy B; Szilágyi M
J Biotechnol; 2019 May; 297():58-65. PubMed ID: 30953675
[TBL] [Abstract][Full Text] [Related]
25. Mir-30b-3p affects the migration and invasion function of ovarian cancer cells by targeting the CTHRC1 gene.
Li Y; Zhou J; Wang J; Chen X; Zhu Y; Chen Y
Biol Res; 2020 Mar; 53(1):10. PubMed ID: 32156314
[TBL] [Abstract][Full Text] [Related]
26. Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features.
Zuberi M; Mir R; Das J; Ahmad I; Javid J; Yadav P; Masroor M; Ahmad S; Ray PC; Saxena A
Clin Transl Oncol; 2015 Oct; 17(10):779-87. PubMed ID: 26063644
[TBL] [Abstract][Full Text] [Related]
27. Ascites-Derived Extracellular microRNAs as Potential Biomarkers for Ovarian Cancer.
Záveský L; Jandáková E; Weinberger V; Minář L; Hanzíková V; Dušková D; Drábková LZ; Svobodová I; Hořínek A
Reprod Sci; 2019 Apr; 26(4):510-522. PubMed ID: 29779470
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA in Ovarian Cancer: Biology, Pathogenesis, and Therapeutic Opportunities.
Chen SN; Chang R; Lin LT; Chern CU; Tsai HW; Wen ZH; Li YH; Li CJ; Tsui KH
Int J Environ Res Public Health; 2019 Apr; 16(9):. PubMed ID: 31035447
[TBL] [Abstract][Full Text] [Related]
29. miRNA profiling in serum and tissue samples to assess noninvasive biomarkers for NSCLC clinical outcome.
Petriella D; De Summa S; Lacalamita R; Galetta D; Catino A; Logroscino AF; Palumbo O; Carella M; Zito FA; Simone G; Tommasi S
Tumour Biol; 2016 Apr; 37(4):5503-13. PubMed ID: 26566629
[TBL] [Abstract][Full Text] [Related]
30. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
[TBL] [Abstract][Full Text] [Related]
31. Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer.
Prahm KP; Høgdall C; Karlsen MA; Christensen IJ; Novotny GW; Høgdall E
PLoS One; 2018; 13(11):e0207319. PubMed ID: 30475821
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA profiling reveals dysregulated microRNAs and their target gene regulatory networks in cemento-ossifying fibroma.
Pereira TDSF; Brito JAR; Guimarães ALS; Gomes CC; de Lacerda JCT; de Castro WH; Coimbra RS; Diniz MG; Gomez RS
J Oral Pathol Med; 2018 Jan; 47(1):78-85. PubMed ID: 29032608
[TBL] [Abstract][Full Text] [Related]
33. Analysis of microRNA (miRNA) expression profiles reveals 11 key biomarkers associated with non-small cell lung cancer.
Wang K; Chen M; Wu W
World J Surg Oncol; 2017 Sep; 15(1):175. PubMed ID: 28927412
[TBL] [Abstract][Full Text] [Related]
34. The role of miRNAs in ovarian cancer pathogenesis and therapeutic resistance - A focus on signaling pathways interplay.
Ismail A; Abulsoud AI; Fathi D; Elshafei A; El-Mahdy HA; Elsakka EGE; Aglan A; Elkhawaga SY; Doghish AS
Pathol Res Pract; 2022 Dec; 240():154222. PubMed ID: 36413828
[TBL] [Abstract][Full Text] [Related]
35. Functions and mechanisms of miR-186 in human cancer.
Wang Z; Sha HH; Li HJ
Biomed Pharmacother; 2019 Nov; 119():109428. PubMed ID: 31525641
[TBL] [Abstract][Full Text] [Related]
36. The ability of miRNAs to induce mesenchymal-to-epithelial transition (MET) in cancer cells is highly dependent upon genetic background.
Zhang M; Wang Y; Matyunina LV; Akbar A; McDonald JF
Cancer Lett; 2020 Jun; 480():15-23. PubMed ID: 32234315
[TBL] [Abstract][Full Text] [Related]
37. Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.
Benson EA; Skaar TC; Liu Y; Nephew KP; Matei D
PLoS One; 2015; 10(10):e0141279. PubMed ID: 26485143
[TBL] [Abstract][Full Text] [Related]
38. Characterization of microRNA expression in serous ovarian carcinoma.
Li Y; Yao L; Liu F; Hong J; Chen L; Zhang B; Zhang W
Int J Mol Med; 2014 Aug; 34(2):491-8. PubMed ID: 24939816
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-153 functions as a tumor suppressor by targeting SET7 and ZEB2 in ovarian cancer cells.
Zhou J; Xie M; Shi Y; Luo B; Gong G; Li J; Wang J; Zhao W; Zi Y; Wu X; Wen J
Oncol Rep; 2015 Jul; 34(1):111-20. PubMed ID: 25954928
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA aberrations: An emerging field for gallbladder cancer management.
Chandra V; Kim JJ; Mittal B; Rai R
World J Gastroenterol; 2016 Feb; 22(5):1787-99. PubMed ID: 26855538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
